Innovent Cost Of Revenue from 2010 to 2024

Pink Sheets . USA . 
Stock . Innovent Biologics
IVBXF Stock  USD 4.85  0.24  4.72%   
Check Innovent Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innovent Biologics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Innovent financial statements analysis is a perfect complement when working with Innovent Biologics Valuation or Volatility modules.
  
This module can also supplement various Innovent Biologics Technical models . Check out the analysis of Innovent Biologics Correlation against competitors.

Currently Active Assets on Macroaxis

ESRTEmpire State Realty
CCitigroup
CCitigroup
GOOGAlphabet Inc Class C
DDDupont De Nemours

Other Information on Investing in Innovent Pink Sheet

Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY